Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Heron Therapeutics
(NQ:
HRTX
)
1.780
+0.040 (+2.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Heron Therapeutics
< Previous
1
2
3
4
5
Next >
7 Unknown Biotech Stocks That Could Rocket in 2023
September 23, 2022
Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline.
Via
InvestorPlace
FDA Approves Heron Therapeutics' Post-Op Nausea Treatment
September 19, 2022
Via
Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
August 31, 2022
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Via
Benzinga
Earnings Outlook For Heron Therapeutics
August 08, 2022
Heron Therapeutics (NASDAQ:HRTX) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
July 26, 2022
Gainers
Via
Benzinga
Earnings Scheduled For February 28, 2022
February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...
Via
Benzinga
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
August 10, 2022
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.
Via
Benzinga
Heron Shares Jump After Equity Financing, Q2 Earnings
August 09, 2022
Via
Benzinga
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
August 09, 2022
Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD....
Via
Benzinga
7 Biotech Stocks to Buy for Q3
July 18, 2022
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential.
Via
InvestorPlace
Stocks That Hit 52-Week Lows On Monday
June 06, 2022
Monday's session saw 84 companies set new 52-week lows.
Via
Benzinga
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
May 09, 2022
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:...
Via
Benzinga
80 Biggest Movers From Yesterday
March 02, 2022
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) jumped 78.5% to close at $0.6066 on Tuesday after jumping 36% on Monday. CTI BioPharma Corp. (NASDAQ: CTIC) surged 63...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 01, 2022
Gainers Avenue Therapeutics (NASDAQ:ATXI) shares rose 172.1% to $0.92 during Tuesday's regular session. As of 12:30 EST, this security is trading at a volume of 157.8...
Via
Benzinga
44 Stocks Moving In Tuesday's Mid-Day Session
March 01, 2022
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) climbed 193% to $0.9962 after jumping 36% on Monday. GBS Inc. (NASDAQ: GBS) rose 73.3% to $0.7971 after declining around 9% on...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 01, 2022
Gainers Avenue Therapeutics (NASDAQ:ATXI) shares rose 102.3% to $0.69 during Tuesday's pre-market session. The market value of their outstanding shares is at $14.3...
Via
Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
March 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...
Via
Benzinga
Heron Therapeutics: Q4 Earnings Insights
February 28, 2022
Heron Therapeutics (NASDAQ:HRTX) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
February 28, 2022
Gainers GBS (NASDAQ:GBS) stock rose 10.9% ...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
Why Heron Therapeutics Shares Rose Nearly 15% This Week
December 09, 2021
The company got approval for an expanded use for its post-surgery pain therapy.
Via
The Motley Fool
Mid-Afternoon Market Update: Nasdaq Falls Over 1%; Reata Pharmaceuticals Shares Plummet
December 09, 2021
Toward the end of trading Thursday, the Dow traded up 0.17% to 35,814.21 while the NASDAQ fell 1.13% to 15,608.30. The S&P also fell, dropping 0.28% to 4,688.20. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
December 09, 2021
Gainers Ensysce Biosciences (NASDAQ:ENSC) shares increased by 88.08% to $5.61 during Thursday's regular session. As of 12:30 EST, Ensysce Biosciences's stock is...
Via
Benzinga
FDA Approves Indication Expansion For Heron Therapeutics' Post-Op Pain Med
December 09, 2021
The FDA has approved Heron Therapeutics Inc's (NASDAQ: HRTX) supplemental application for Zynrelef (bupivacaine and meloxicam) extended-release solution to...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
November 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...
Via
Benzinga
Topics
Retirement
Exposures
Pension
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Bluebird Bio or Heron Therapeutics: Which Stock Is the Better Comeback Play?
October 11, 2021
These once-promising biotech stocks are trading at a fraction of their all-time highs right now.
Via
The Motley Fool
Markets Of The Apes
September 23, 2021
A discussion and review on the markets.
Via
Talk Markets
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
October 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...
Via
Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
October 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.